Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2016 Feb 10;11(2):e0149014. doi: 10.1371/journal.pone.0149014

Hydrophobic Interactions Are a Key to MDM2 Inhibition by Polyphenols as Revealed by Molecular Dynamics Simulations and MM/PBSA Free Energy Calculations

Sharad Verma 1, Sonam Grover 2, Chetna Tyagi 1, Sukriti Goyal 3, Salma Jamal 3, Aditi Singh 4, Abhinav Grover 1,*
Editor: Freddie Salsbury Jr5
PMCID: PMC4749206  PMID: 26863418

Abstract

p53, a tumor suppressor protein, has been proven to regulate the cell cycle, apoptosis, and DNA repair to prevent malignant transformation. MDM2 regulates activity of p53 and inhibits its binding to DNA. In the present study, we elucidated the MDM2 inhibition potential of polyphenols (Apigenin, Fisetin, Galangin and Luteolin) by MD simulation and MM/PBSA free energy calculations. All polyphenols bind to hydrophobic groove of MDM2 and the binding was found to be stable throughout MD simulation. Luteolin showed the highest negative binding free energy value of -173.80 kJ/mol followed by Fisetin with value of -172.25 kJ/mol. It was found by free energy calculations, that hydrophobic interactions (vdW energy) have major contribution in binding free energy.

Introduction

p53, a tumor suppressor protein, has critical role in regulation of the cell cycle, apoptosis, and DNA repair to prevent malignant transformation [13]. Over expressed MDM2 regulates activity of p53 and inhibits its binding with DNA in tumors [4]. Several peptide inhibitors that mimic p53 have been reported but they exhibit modest effects because they have poor membrane permeability [59]. The structure of MDM2 (p53 binding region) consists a hydrophobic groove like structure formed by two helices and a loop. Two sheet structures form the back of groove (Fig 1). The important residues Leu54, Leu57, Gly58, Ile61, Met62, Tyr67, Gln72, His73, Val75, Phe91, Val93, His96, Ile99 and Tyr100 are together known as the structural component which interacts with p53 residues [10, 11]. Naturally occurring polyphenolic phytochemicals have been reported to inhibit cancer [12, 13] and also show potential binding to MDM2 in its hydrophobic grooves [14, 15]. In this study, we tried to elucidate the binding of polyphenols (Apigenin, Fisetin, Galangin and Luteolin) (Fig 2) to MDM2 groove with the help of molecular docking and molecular dynamic simulation along with MM/PBSA free energy calculations.

Fig 1. Structure of p53 binding domain of MDM2 (A) Ribbon, (B) Surface.

Fig 1

Fig 2. Structure of polyphenols.

Fig 2

Apigenin is widely found in many fruits and vegetables, including chamomile, parsley, onions, tea, orange and wheat sprouts [16]. Fisetin is present in strawberries, apples, persimmons, kiwis, cucumbers and onions [17]. Galangin is a found in Alpinia officinarum (lesser galangal) [18]. Luteolin concentrations are found in peanut hulls and in Reseda luteola L., the Dyer's weld are high as compared to food [19, 20].

Materials and Methods

Molecular Docking of natural polyphenols at the MDM2 groove

Molecular-docking was performed using molecular docking suite AutoDock 4.0. The crystal structure of MDM2 (PDB ID 1RV1) was obtained from the RCSB protein data bank. The structures of polyphenols (Apigenin, Fisetin, Galangin and Luteolin) were generated from SMILE strings. All the heteroatoms were removed during the preparation of protein coordinate file. All the missing atoms were repaired by AutoDock. Adaptive local search based Lamarckian genetic algorithm [21] was used as a search parameter. Short range van der Waals and electrostatic interactions, hydrogen bonding, entropy losses were included for energy-based AutoDock scoring function [21, 22]. In the study, the Lamarckian GA parameters used were the number of runs, 20; population size, 150; the maximum number of eval, 250,00,000; the number of generations, 27,000; rate of gene mutation, 0.02; and the rate of cross over, 0.8. Blind docking is carried out using grid size of 126 × 126 × 126 along the X, Y, and Z axes with 0.375 Å spacing. RMS cluster tolerance was set to 2.0 Å.

Molecular dynamic simulation

MD simulation of the complex was carried out using the GROMOS96 43a1 force field [23, 24] of the GROMACS 4.5.4 package. Autodock generated lowest binding energy (most negative) docking conformation of MDM2–polyphenol complex which was taken as the initial conformation for MD simulation. The topology parameters of proteins were created by means of the Gromacs program. The topology parameters of taxifolin were built using the Dundee PRODRG server [25]. The complex was immersed in a cubic box of extended simple point charge water molecules [26, 27]. Energy minimization was performed using the steepest descent method of 10,000 steps followed by the conjugate gradient method for 10,000 steps, to release conflicting contacts. Position-restrained dynamics simulation (equilibration phase) (NVT and NPT) of the system was done at 300 K for 200 ps followed by MD production run for 15 ns. For the purpose of analysis, the atomic coordinates were recorded every 1.0 ps during the MD simulation. All the structural images were generated using Chimera [28].

Binding free energy calculations

The molecular mechanics Poisson Boltzmann surface area (MM/PBSA) method [29] is the widely used method for binding free energy calculations from the snapshots of MD trajectory. The binding free energies of the complexes between polyphenols and MDM2 were analyzed during equilibrium phase by taking snapshots at an interval of 1.5 ps from 13 to 15 ns MD simulations, using g_mmpbsa tool of Gromacs [30].

Particularly, the binding free energy of ligand-protein complex in solvent was expressed as:

ΔGbinding = Gcomplex - (Gprotein + Gligand)

where Gcomplex is the total free energy of the protein-ligand complex, Gprotein and Gligand are total energy of separated protein and ligand in solvent, respectively. The free energy for each individual Gcomplex, Gprotein and Gligand were estimated by:

Gx = EMM + Gsolvation

where x is the protein, ligand, or complex. EMM is the average molecular mechanics potential energy in vacuum and Gsolvation is free energy of solvation. The molecular mechanics potential energy was calculated in vacuum as following:

EMM = Ebonded + Enon-bonded = Ebonded + (Evdw + Eelec)

where Ebonded is bonded interaction including of bond, angle, dihedral and improper interactions and Enon-bonded is non-bonded interactions consisting of van der Waals (Evdw) and electrostatic (Eelec) interactions. ΔEbonded is always taken as zero [31].

The solvation free energy (Gsolvation) was estimated as the sum of electrostatic solvation free energy (Gpolar) and apolar solvation free energy (Gnon-polar):

Gsolvation = Gpolar + Gnon-polar

where Gpolar was computed using the Poisson-Boltzmann (PB) equation [29] and Gnon-polar estimated from the solvent-accessible surface area (SASA) as equation following:

Gnon-polar = γSASA + b

where γ is a coefficient related to surface tension of the solvent and b is fitting parameter. The values of the contats are as follows:

γ = 0.02267 Kj/Mol/Å2 or 0.0054 Kcal/Mol/Å2

b = 3.849 Kj/Mol or 0.916 Kcal/Mol

Principal component analysis (PCA)

PCA was performed to obtain a mass-weighted covariance matrix of the protein atom displacement which is indicative of dominant and collective modes of the protein from the overall dynamics of the MD trajectory. This covariance matrix is diagonalized to extract a set of eigenvectors and eigenvalues that reflect concerted motion of the molecule [3235]. The Gromacs in-built tool g_covar was used to yield the eigenvalues and eigenvectors by calculating and diagonalizing the covariance matrix, whereas the g_anaeig tool was used to analyze and plot the eigenvectors [34].

Results and Discussion

Molecular docking results revealed that Apigenin, Fisetin, Galangin and Luteolin bind to hydrophobic groove of MDM2 with lowest binding energy values of (most negative) -5.62, -6.02, -5.78 and -6.39 kcal/mol respectively. These docking conformations of MDM2-polyhenol complexes, generated by Autodock, were taken as initial conformation for MD simulation. Fig 3A shows that the RMSD profiles were always less than 0.25 nm for all ligands bound to MDM2 backbone during the entire simulation suggesting the suitability of MD simulation run. Fig 3B shows the RMSF profile of MDM2. In all the complexes, MDM2 showed fluctuation within the range of 0.30 nm in a very similar pattern.

Fig 3.

Fig 3

(A) backbone RMSD of MDM2 (Red-apigenin, Green- fisetin, Blue-galangin, Purple-luteolin), (B) RMSF profile of MDM2 (Red-apigenin, Green- fisetin, Blue-galangin, Purple-luteolin).

The root mean square distance between center of gravity and ends of an object denotes radius of gyration (Rg). The radius of gyration provides indication about the level of compaction in the protein structure. Apigenin and Fisetin bound MDM2 showed slightly increased radius of gyration while Galangin and Luteolin bound MDM2 showed slightly decreased radius of gyration (Fig 4A). Solvent accessible surface area (SASA) indicates the solvent exposed surface of protein and hence the folding of exposed part of proteins. Galangin bound MDM2 showed slightly increased SASA while other polyphenol bound MDM2 showed slightly decreased SASA (Fig 4B).

Fig 4.

Fig 4

(A) Radius of gyration profile of MDM2 (Red-apigenin, Green- fisetin, Blue-galangin, Purple-luteolin)., (B) SASA profile of MDM2 (Red-apigenin, Green- fisetin, Blue-galangin, Purple-luteolin).

Analysis of final pose of MDM2-ligand complex after 15 ns molecular dynamics simulation revealed that polyphenols stably bound to the hydrophobic groove. Fig 5A shows Apigenin surrounded by the MDM2 hydrophobic groove residues. Comparative surface analysis of final and initial structures revealed significant conformational changes. Residues were found to overlap with bound Apigenin (Fig 5B). Even as the binding site for all the polyphenols is same, yet Fisetin, Galangin and Luteolin brought more significant change in the hydrophobic groove and were found to be deeply penetrated in the groove as shown in Figs 6, 7 and 8 respectively. These polyphenols induced deep pore-like structure and could accommodate in it.

Fig 5. Apigenin-MDM2 complex at 15 ns (A) cartoon representation, (B) surface structure.

Fig 5

Fig 6. Fisetin-MDM2 complex at 15 ns (A) cartoon representation, (B) surface structure.

Fig 6

Fig 7. Galangin-MDM2 complex at 15 ns (A) cartoon representation, (B) surface structure.

Fig 7

Fig 8. Luteolin-MDM2 complex at 15 ns (A) cartoon representation, (B) surface structure.

Fig 8

The interaction plot, generated by Ligplot [36] showed massive hydrophobic interaction between residues and polyphenols. The interacting residues include Ile61, Met62, His73, Tyr67, Leu58, Phe86, Val93 and Ile99 (Fig 9). These residues have been known to interact with p53 residues through previous studies [10, 11].

Fig 9. Polyphenol-MDM2 interaction plot generated by Ligplot (A) Apigenin, (B) Fisetin, (C) Galangin, (D) Luteolin.

Fig 9

Free energy calculations

Molecular dynamic simulations were used to calculate binding free energy using MM/PBSA method. Snapshots were extracted at every 15 ps of stable intervals from 13–15 ns MD trajectory. The binding free energy and its corresponding components obtained from the MM/PBSA calculation of the MDM2-polyphenol complexes are listed in Table 1. The results indicated that Luteolin possessed highest negative binding free energy value of -173.80 kJ/mol followed by Fisetin with value of -172.25 kJ/mol. Apigenin and Galangin showed affinity with value of -139.48 and -142.48 kJ/mol, respectively.

Table 1. Average MM/PBSA free energies of MDM2-polyphenol complexes calculated from the MD simulations performed in triplicate.

Ligands Van der waal (kJ/mol) Electrostattic (kJ/mol) Polar salvation (kJ/mol) Non-polar salvation (kJ/mol) Binding energy (kJ/mol)
Apigenin -149.81±11.91 -23.65±1.41 47.08±10.91 -14.22±0.76 -139.48±3.53
Fisetin -154.62±1.20 -36.39±13.53 32.29±0.23 -13.74±0.50 -172.25±13.70
Galangin -152.04±13.27 -12.98±5.90 36.54±4.60 -13.01±0.93 -142.48±1.40
Luteolin -170.40±20.29 -12.42±9.10 23.84±0.97 -14.82±0.028 -173.80±4.34

Moreover, van der Waals and electrostatic interactions and non-polar solvation energy negatively contribute to the total interaction energy while only polar solvation energy positively contributes to total free binding energy. In terms of negative contribution, van der Waals interaction gives much larger contribution than electrostatic interactions for all the cases. The non-polar free energy contributes relatively less as compared to the total binding energy. This indicates that non-polar solvation energy, van der Waals and electrostatic interaction together contribute to the MDM2-polyphenol complex stability. From the data collected by mm/pbsa calculations and the interaction plot generated by ligplot, it is seen that hydrophobic interactions are dominant in all complexes. High negative value of vdW energy represents the massive hydrophobic interaction between MDM2 and polyphenols.

Analysis of final snapshot at 15 ns revealed that Luteolin and Fisetin deeply penetrate into the hydrophobic groove. The loop (residue 41 to 49) was found to be in closer proximity in Luteolin and Fisetin bound MDM2 (Fig 10). These can be possible reasons responsible for the higher hydrophobic interaction with Luteolin and Fisetin and possible reason of higher binding energy. The sheet structures were absent in the Luteolin bound form which may confer the flexibility of groove and facilitate the penetration of Luteolin.

Fig 10. Penetration of polyphenol in hydrophobic groove of MDM2.

Fig 10

Principal component analysis (PCA)

The MD trajectory of system was inspected with the principal components to better understand the conformational changes of MDM2 with all polyphenol bound forms. Correlated motion plot shows how atoms move relative to each other. Motions can be positively correlated (in the same direction), anti-correlated (in the opposite direction), or uncorrelated [37]. The positive and negative limits are shown in Fig 11. Anti-correlated motions were dominant in all the forms. Summary of significant motions is presented in Table 2. These motions collectively drive the structure of hydrophobic groove and also the intensity of hydrophobic interaction. Difference in final hydrophobic groove structure of MDM2 forms can be observed in Figs 5B to 8B.

Fig 11. Covariance matrix of MDM2 during 15 ns MD simulation (Upper left-Apigenin, Upper right-Fisetin, Lower left-Galangin, Lower right-Luteolin).

Fig 11

Table 2. Dominant motions of atom in helix2, helix 4 and loop.

Helix 2-Helix 4 Helix 2-Loop Loop-Helix 4
Apigenin Anti-correlated, anticorrelated with helix 4 terminal residues Strongly anticorrelated Mixed (anticorrelated and correlated)
Fisetin Anti-correlated, anticorrelated with helix 4 terminal residues Anticorrelated Mixed (anticorrelated and correlated)
Galangin Anti-correlated, uncorrelated with helix 4 terminal residues Anticorrelated Mixed (anticorrelated and uncorrelated)
Lueolin Anti-correlated, uncorrelated with helix 4 terminal residues Weakly anticorrelated uncorrelated

Nutlin-3 is a well-known inhibitor of p53-MDM2 interaction and activates p53 in cancer cells [1, 3840]. Nutlin-3a, which is an active emantiomer of Nutlin-3, is an MDM2 antagonist and found to be very effective in the treatment of Ewing’s sarcoma cells [4143]. Nutlin-3a and polyphenols shared similar binding site on MDM2. The binding energy value for MDM2-Nutlin-3a complex was -9.11 kcal/Mol [44] calculated by MM/PBSA method which is very high as compared to polyphenols. However in case of nutlin binding energy found to be -43.5 kcal/Mol (entropic term is not included) which is slightly lower than polyphenols. Same study noted that the MDM2-nutlin interaction driven by the van der Waals interactions as in case of polyphenols [45]. This comparison revealed that polyphenols (Apigenin, Fisetin, Galangin and Luteolin) have tremendous potential to act as the MDM2 inhibitors.

Conclusions

All polyphenols (Apigenin, Fisetin, Galangin and Luteolin) bind to hydrophobic groove of MDM2 and the binding was found to be stable throughout MD simulation. Luteolin binds with highest negative binding energy value and shows highest potency towards MDM2 inhibition. Although, the MDM2 residues interacting with polyphenols were the same for all but, the change in groove structure significantly affected the position of polyphenol in the groove and also its binding energy. The hydrophobic interactions were solely responsible for stable complex formation as revealed by the vdW energy and ligplot analysis. Finally, on the basis of data obtained during the study, it can be concluded that these polyphenols have the potential to be used as lead molecules for the inhibition of MDM2 with Luteolin being the top candidate. This approach can be used to screen out a huge number of natural compounds for their potency in anti-cancer treatment.

Acknowledgments

SV is thankful to Council of Scientific and Industrial Research (CSIR), India for providing senior research associateship (pool scientist scheme). AG is thankful to Jawaharlal Nehru University for usage of all computational facilities. AG is grateful to University Grants Commission, India for the Faculty Recharge Position.

Data Availability

All relevant data are within the paper.

Funding Statement

The authors have no support or funding to report.

References

  • 1.Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303: 844–848. [DOI] [PubMed] [Google Scholar]
  • 2.Vogelstein B, Lane D, Levine AJ. The p53 tumour-suppressor gene integrates numerous signals that control cell life and death, as when a highly connected node in the Internet breaks down, the disruption of p53 has severe consequences. Nature. 2000; 408: 307–310.11099028 [Google Scholar]
  • 3.Levine AJ. P53, the cellular gatekeeper for growth and division. Cell. 1997; 88: 323–331. [DOI] [PubMed] [Google Scholar]
  • 4.Dastidar SG, Lane DP, Verma CS. Modulation of p53 binding to MDM2: computational studies reveal important role of Tyr 100, BMC bioinformatics Proceedings. 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bautista AD, Appelbaum JS, Craig CJ, Michel J, Schepartz A. Bridged a3- peptide Inhibitors of p53–hDM2complexation: correlation between affinity and cell permeability. J Am Chem Soc. 2010; 132: 2904–2906. 10.1021/ja910715u [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Fasan R, Dias RLA, Moehle K, Zerbe O, Vrijbloed JW, Obrecht D, et al. Using a ß-hairpin to mimic alpha-helix-novel cyclic peptidomimetic inhibitors of the p53–HDM2 protein—protein interaction. Angew Chem Int Ed. 2004; 43: 2109–2112. [DOI] [PubMed] [Google Scholar]
  • 7.Kritzer JA, Lear JD, Hodsdon ME, Schepartz A. Helical a-peptide inhibitors of the p53–hDM2 interaction. J Am Chem Soc. 2004; 126:9468–9469. [DOI] [PubMed] [Google Scholar]
  • 8.Stoll R, Renner C, Hansen S, Palme S, Klein C, Belling A, et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochem. 2001; 40: 336–344. [DOI] [PubMed] [Google Scholar]
  • 9.Zhao J, Wang M, Chen J, Luo A, Wang X, Wu M, et al. The initial evaluation of nonpeptidic small-molecule HDM2 inhibitors based on p53–HDM2 complex structure. Cancer Lett. 2002; 183: 69–77. [DOI] [PubMed] [Google Scholar]
  • 10.Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996; 274: 948–953. [DOI] [PubMed] [Google Scholar]
  • 11.Fu T, Min H, Xu Y, Chen J, Li G. Molecular Dynamic Simulation Insights into the Normal State and Restoration of p53 Function. Int J Mol Sci 2012; 13: 9709–9740. 10.3390/ijms13089709 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Lee SB, Cha KH, Selenge D, Solongo A, Nho CW. The Chemopreventive Effect of Taxifolin Is Exerted through ARE-Dependent Gene Regulation. Biol Pharm Bull. 2007; 30:1074–1079. [DOI] [PubMed] [Google Scholar]
  • 13.Seufi AM, Ibrahim SS, Elmaghraby TK, Hafez EE. Preventive effect of the flavonoid, quercetin, on hepatic cancer in rats via oxidant/ antioxidant activity: molecular and histological evidences. J Exp Clin Cancer Res. 2009; 28: 80 10.1186/1756-9966-28-80 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Verma S, Singh A, Mishra A. Molecular Dynamics Investigation on the Inhibition of MDM2-p53 Interaction by Polyphenols, Mol Informatics. 2013; 32: 203–212. [DOI] [PubMed] [Google Scholar]
  • 15.Verma S, Singh A, Mishra A. Quercetin and taxifolin completely break MDM2–p53 association: molecular dynamics simulation study, Med Chem Res. 2012; 22: 2778–2787. [Google Scholar]
  • 16.Birt DF, Mitchell D, Gold B, Pour P, Pinch HC. Inhibition of ultraviolet light induced skin carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid. Anticancer Res. 1997, 17:85–91. [PubMed] [Google Scholar]
  • 17.Kimira M, Arai Y, Shimoi K, Watanabe S. Japanese intake of flavonoids and isoflavonoids from foods. J Epidemiol. 1998; 8:168–75. [DOI] [PubMed] [Google Scholar]
  • 18.Miyajima Y, Kikuzaki H, Hisamoto M, Nakatani N. Antioxidative polyphenols from berries of Pimenta dioica. Biofactors. 2004; 22: 301–303. [DOI] [PubMed] [Google Scholar]
  • 19.Seelinger G, Merfort I, Wölfle U, Schempp CM. Anti-carcinogenic Effects of the Flavonoid Luteolin. Molecules 2008; 13: 2628–2651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lin Y, Shi R, Wang X, Shen H. Luteolin, a flavonoid with potentials for cancer prevention and therapy. Curr Cancer Drug Targets. 2008; 8: 634–646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Morris GM, Goodsell DS, Halliday RS. Automated Docking Using a Lamarckian Genetic Algorithm and Empirical Binding Free Energy Function. J Comp Chem. 1998; 19: 1639–1662 [Google Scholar]
  • 22.Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009; 30: 2785–2791. 10.1002/jcc.21256 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Berendsen HJC, Van der Spoel D, Van Drunen R. GROMACS—A Message-passing parallel molecular dynamics implementation. Phys Commun. 1995; 91: 43–56. [Google Scholar]
  • 24.Lindah E, Hess B, Van der Spoel D. Gromacs 3.0: a package for molecular simulation and trajectory analysis. J Mol Model. 2001; 7: 306–317. [Google Scholar]
  • 25.Schuttelkopf AW, van Aalten DM. PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. 2004; 60: 1355–1363. [DOI] [PubMed] [Google Scholar]
  • 26.Van Gunsteren WF, Billeter SR, Eising AA, Hünenberger PH, Krüger P, Mark AE, et al. Biomolecular simulation: the GROMOS96 manual and user guide. Vdf Hochschulverlag AG, Zurich. 1996.
  • 27.Van Gunsteren WF, Daura X, Mark AE. The GROMOS force field In: VonRague Schleyer P (ed)Encyclopedia of computational chemistry, vol 2Wiley and Sons, Chichester, 1998: 1211–1216. [Google Scholar]
  • 28.Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2005; 25: 1605–1612. [DOI] [PubMed] [Google Scholar]
  • 29.Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res. 2000; 33: 889–897. [DOI] [PubMed] [Google Scholar]
  • 30.Kumari R, Kumar R, Open Source Drug Discovery Consortium, Lynn A. g_mmpbsa:A GROMACS Tool for High-Throughput MM-PBSA Calculations. J Chem Inf Model. 2014; 54: 1951–1962. 10.1021/ci500020m [DOI] [PubMed] [Google Scholar]
  • 31.Homeyer N, Gohlke H. Free Energy Calculations by the Molecular Mechanics Poisson—Boltzmann Surface Area Method. Mol Inform. 2012; 31:114–122. [DOI] [PubMed] [Google Scholar]
  • 32.Amadei A, Linssen AB, Berendsen HJ. Essential dynamics of proteins. Proteins. 1993; 17: 412–425. [DOI] [PubMed] [Google Scholar]
  • 33.Yamaguchi H, van Aalten DM, Pinak M, Furukawa A, Osman R. Essential dynamics of DNA containing a cis.syncyclobutane thymine dimer lesion. Nucleic Acids Res. 1998; 26: 1939–1946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.van Aalten DM, Findlay JB, Amadei A, Berendsen HJ. Essential dynamics of the cellular retinol-binding protein—evidence for ligand-induced conformational changes. Protein Eng. 1995; 8: 1129–1135. [DOI] [PubMed] [Google Scholar]
  • 35.Gosu V, Choi S. Structural dynamic analysis of apo and ATP-bound IRAK4 kinase. Sci Rep. 2014; 4: 5748 10.1038/srep05748 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1996; 8: 127–134. [DOI] [PubMed] [Google Scholar]
  • 37.Jonesa JC, Jones AM, Templea BRS, Dohlmana HG. Differences in intradomain and interdomain motion confer distinct activation properties to structurally similar Gα proteins. Proc Nat Acad Sci USA. 2012; 109: 7275–7279. 10.1073/pnas.1202943109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303: 844–848. [DOI] [PubMed] [Google Scholar]
  • 39.Muller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3a. Int J Cancer. 2007; 121: 199–205. [DOI] [PubMed] [Google Scholar]
  • 40.Van Maerken T, Speleman F, Vermeulen J, Lambertz I, De Clercq S, De Smet E, et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res. 2006; 66: 9646–9655. [DOI] [PubMed] [Google Scholar]
  • 41.Zauli G, Rimondi E, Corallini F, Fadda R, Capitani S, Secchiero P. MDM2 Antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway. J Bone Miner Res. 2007; 22: 1621–1630. [DOI] [PubMed] [Google Scholar]
  • 42.Sonnemann J, Palani CD, Wittig S, Becker S, Eichhorn F, Voigt A, et al. Anticancer effects of the p53 activator nutlin-3 in Ewing’s sarcoma cells. Eur J Cancer. 2011; 47: 1432–1441. 10.1016/j.ejca.2011.01.015 [DOI] [PubMed] [Google Scholar]
  • 43.Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, et al. Nutlin-3a is a potential therapeutic for Ewing sarcoma. Clin Cancer Res 2011, 17: 494–504. 10.1158/1078-0432.CCR-10-1587 [DOI] [PubMed] [Google Scholar]
  • 44.Bozzi F, Conca E, Laurini E, Posocco P, Lo Sardo A, Jocolle G, et al. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas. Lab Invest. 2013; 93: 1232–1240. 10.1038/labinvest.2013.107 [DOI] [PubMed] [Google Scholar]
  • 45.Joseph TL, Madhumalar A, Brown CJ, Lane DP, Verma CS. Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies. Cell Cycle. 2010; 9: 1167–1181. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

All relevant data are within the paper.


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES